March 30 Update: New Information on Diagnostic Testing for SARS-CoV-2
March 31, 2020
Thank you for your interest in development of diagnostics for SARS-CoV-2. On March 30, 2020, the FDA updated the frequently asked questions on diagnostic testing to include new and updated information on:
- When FDA authorizes a SARS-CoV-2 test for use at the point of care, does that mean it is CLIA waived?
- I am developing a COVID-19 assay that is a modification of a previously EUA authorized COVID-19 assay. Do I need to start from scratch with my validation or can I validate my test with a bridging study?
Recent News
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis